Lv3
230 积分 2025-02-14 加入
[Explanation of the experts consensus on diagnosis and treatment of laryngeal leukoplakia]
1个月前
已完结
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D
2个月前
已完结
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2个月前
已完结
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
2个月前
已完结
Synthetic lethality and cancer
2个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2个月前
已完结
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
2个月前
已完结
Artificial intelligence in drug development
2个月前
已完结
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
2个月前
已完结
Targeting DNA damage response pathways in cancer
2个月前
已完结
皖公网安备34019202002308
